These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8422232)
1. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs. Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232 [TBL] [Abstract][Full Text] [Related]
2. Experimental evaluation of the V-point heparin-bonding system applied to a dense-membrane artificial lung during 24-hour extracorporeal circulation in beagles. Tashiro M; Okamoto T; Sakanashi Y; Ao H; Imaizumi T; Tanimoto H; Yanagi F; Sugita M; Mimura R; Terasaki H Artif Organs; 2001 Aug; 25(8):655-63. PubMed ID: 11531718 [TBL] [Abstract][Full Text] [Related]
3. A new heparin-bonded dense membrane lung combined with minimal systemic heparinization prolonged extracorporeal lung assist in goats. Okamoto T; Tashiro M; Sakanashi Y; Tanimoto H; Imaizumi T; Sugita M; Terasaki H Artif Organs; 1998 Oct; 22(10):864-72. PubMed ID: 9790085 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a new heparin-coated dense membrane lung with nonheparin-coated dense membrane lung for prolonged extracorporeal lung assist in goats. Ichinose K; Okamoto T; Tanimoto H; Yoshitake A; Tashiro M; Sakanashi Y; Kuwana K; Tahara K; Kamiya M; Terasaki H Artif Organs; 2004 Nov; 28(11):993-1001. PubMed ID: 15504115 [TBL] [Abstract][Full Text] [Related]
5. Heparin bonding of the extracorporeal circuit reduces thrombosis during prolonged lung assist in goats. Ao H; Tajiri A; Yanagi F; Okamoto T; Tashiro M; Sakanashi Y; Tanimoto H; Moon JK; Terasaki H ASAIO J; 2000; 46(6):723-9. PubMed ID: 11110270 [TBL] [Abstract][Full Text] [Related]
6. [Changes in platelets and blood coagulation during prolonged ECLA with a heparin bonded hollow fiber membrane lung]. Ezaki K Masui; 1990 Jul; 39(7):845-53. PubMed ID: 2214119 [TBL] [Abstract][Full Text] [Related]
7. Total and prolonged filling of the lungs with Ringer's solution under extracorporeal lung assist (ECLA) in dogs. Sakanashi Y; Tanimoto H; Okamoto T; Tashiro M; Ao H; Terasaki H Acta Anaesthesiol Scand; 2000 Sep; 44(8):994-1001. PubMed ID: 10981579 [TBL] [Abstract][Full Text] [Related]
8. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report. Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748 [TBL] [Abstract][Full Text] [Related]
9. Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep. Oedekoven B; Bey R; Mottaghy K; Schmid-Schönbein H Thromb Haemost; 1984 Dec; 52(3):329-32. PubMed ID: 6442472 [TBL] [Abstract][Full Text] [Related]
10. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit]. Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086 [TBL] [Abstract][Full Text] [Related]
11. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS). Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588 [TBL] [Abstract][Full Text] [Related]
12. Nafamostat mesilate, a synthetic protease inhibitor, attenuated hypercoagulability in a canine model of hemorrhagic shock. Koido Y; Kato K; Shimizu-Suganuma M; Shichinohe K Nihon Ika Daigaku Zasshi; 1997 Feb; 64(1):9-15. PubMed ID: 9119959 [TBL] [Abstract][Full Text] [Related]
13. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant. Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059 [TBL] [Abstract][Full Text] [Related]
14. Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients. Gerlach M; Föhre B; Keh D; Riess H; Falke KJ; Gerlach H Int J Artif Organs; 1997 Jan; 20(1):29-36. PubMed ID: 9062829 [TBL] [Abstract][Full Text] [Related]
15. Safety of high-dose of nafamostat mesilate: toxicological study in beagles. Okamoto T; Mizoguchi S; Terasaki H; Morioka T J Pharmacol Exp Ther; 1994 Feb; 268(2):639-44. PubMed ID: 8113974 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs. Choi JH; Byun SY; Nam A; Han SM; Lee KP; Song KH; Youn HY; Seo KW J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):122-129. PubMed ID: 29419934 [TBL] [Abstract][Full Text] [Related]
17. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. Han SJ; Kim HS; Kim KI; Whang SM; Hong KS; Lee WK; Lee SH J Korean Med Sci; 2011 Jul; 26(7):945-50. PubMed ID: 21738350 [TBL] [Abstract][Full Text] [Related]
18. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation]. Akizawa T Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168 [TBL] [Abstract][Full Text] [Related]
19. The effects of pre-arrest heparin administration dose for cardiac arrest model using extracorporeal lung and a heart assist (ECLHA) in dogs. Ichinose K; Okamoto T; Tashiro M; Tanimoto H; Terasaki H Resuscitation; 2006 May; 69(2):311-8. PubMed ID: 16460866 [TBL] [Abstract][Full Text] [Related]
20. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study. Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]